Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With Anti-CD20 Monoclonal Antibody-CVP Regimen for the Treatment of Previously Untreated Marginal Zone Lymphoma
NCT07480863Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Complete Remission Rate at 24 months. Started Oct 2025; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07480863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480863.